Skip to main content

Hybrigenics Signs Three-Year, $2.4M Renewal of Protein Interaction Services Deal


French biotech firm Hybrigenics said this week that it has renewed a three-year, $2.4 million research services agreement with an unnamed US life sciences company.

Under the agreement, Hybrigenics will continue to offer its two-hybrid screens and build databases of protein interactions identified through these screens.

The new deal follows an initial three-year agreement that began in 2009. Under the new terms, the annual fee due Hybrigenics has increased from $700,000 to $790,000.

Hybrigenics has an R&D program aimed at developing treatments for diseases including prostate cancer and psoriasis, but the bulk of its revenues come from its fee-for-service protein interaction work, which is housed within its Hybrigenics Services component — a fully owned subsidiary the company created in July 2010. In the first half of 2012, its protein interaction services generated €1.4 million ($1.8 million) of the firm's total €2 million in revenues.

Clients for these services include firms like Pfizer, GlaxoSmithKline, and L'Oreal, as well as academic customers like Harvard and Johns Hopkins University.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.